Last updated: September 5, 2026
Follitropin beta is a mature recombinant follicle-stimulating hormone marketed primarily as Follistim AQ in the United States. Its commercial value is supported by assisted reproductive technology demand, physician familiarity, and delivery-device differentiation rather than active-ingredient exclusivity. Organon controls the U.S. commercial franchise, but does not report Follistim revenue as a standalone line item. Long-term risks are generic or follow-on biologic competition, price pressure from follitropin alfa, and fertility-treatment reimbursement constraints.
What is follitropin beta and how is it used?
Follitropin beta is recombinant human FSH manufactured in genetically modified Chinese hamster ovary cells. It stimulates ovarian follicular development and is used for:
- Ovulation induction in patients with anovulatory infertility.
- Controlled ovarian stimulation for in vitro fertilization and other assisted reproductive technologies.
- Spermatogenesis induction in selected men with hypogonadotropic hypogonadism, when used with human chorionic gonadotropin.
The principal U.S. product is Follistim AQ, an injectable formulation supplied in cartridges for use with the Follistim Pen. The FDA label identifies ovarian hyperstimulation syndrome, multiple gestations, thromboembolic events and ovarian enlargement among the major clinical risks. [1]
Follitropin beta is not a small-molecule fertility drug. It is a recombinant biologic whose manufacturing process, glycosylation profile, potency testing, formulation and delivery system affect product comparability.
Who markets follitropin beta?
Organon is the principal commercial owner and marketer of Follistim in the United States. The product originated within the Merck fertility portfolio. Merck separated its established brands and women’s health businesses into Organon in 2021, transferring the relevant commercial operations to the new company. [2]
| Product |
Active ingredient |
Principal marketer |
Primary use |
Commercial position |
| Follistim AQ |
Follitropin beta |
Organon |
Ovulation induction and ART |
Established recombinant FSH brand |
| Gonal-f |
Follitropin alfa |
EMD Serono/Merck KGaA affiliates |
Ovulation induction and ART |
Primary branded competitor |
| Rekovelle |
Follitropin delta |
Ferring |
Controlled ovarian stimulation |
Newer individualized dosing approach |
| Menopur |
Menotropins |
Ferring |
Ovulation induction and ART |
Urinary-derived gonadotropin |
| Bravelle |
Urofollitropin |
Ferring |
Ovulation induction and ART |
Urinary-derived FSH product |
The competitive market is divided by treatment protocol, physician preference, clinic purchasing arrangements, payer coverage, pen convenience and perceived consistency of recombinant products.
How large is the follitropin beta market?
No major manufacturer publicly reports standalone global revenue for follitropin beta. Organon reports revenue by broader product categories and therapeutic franchises rather than providing a separate Follistim revenue line. This prevents a reliable public calculation of the product’s annual sales, geographic contribution or exact market share.
The commercial market is driven by the number of fertility-treatment cycles rather than by chronic daily use. Patients generally receive FSH for a limited stimulation period, with dosing determined by ovarian reserve, age, body weight, treatment protocol and response.
Demand has several structural supports:
- Rising maternal age at first birth increases the use of fertility evaluation and assisted reproduction.
- IVF and other ART procedures are expanding in markets with improving reimbursement and private-pay capacity.
- Infertility treatment is becoming more accessible through employer benefits, fertility clinics and specialized financing.
- Recombinant FSH remains a standard component of controlled ovarian stimulation.
Demand is constrained by treatment cost, insurance exclusions, fertility-drug authorization requirements and the ability of clinics to shift between recombinant FSH, urinary gonadotropins and alternative stimulation protocols.
The Centers for Disease Control and Prevention reports ART activity and outcomes in the United States but does not isolate revenue by gonadotropin product. Its data confirm that ART is a high-volume, protocol-driven market in which medication selection is only one component of total treatment cost. [3]
What is the financial trajectory for Follistim?
Follistim is best analyzed as a mature cash-generating product within Organon’s established women’s health portfolio, not as a high-growth biotechnology asset.
Revenue visibility
Organon’s public filings do not identify Follistim revenue separately. The product is included within broader women’s health or fertility-related commercial reporting. As a result:
- Standalone annual sales are not publicly verifiable.
- Product-level growth rates cannot be calculated from Organon’s consolidated filings.
- Regional revenue exposure cannot be separated reliably from other fertility products.
- Reported corporate performance should not be attributed directly to Follistim.
Organon’s financial trajectory depends on the combined performance of established brands, biosimilars, women’s health products and other medicines. Follistim contributes to the established-products base, where volume stability and price management are generally more important than rapid unit expansion. [2]
Likely commercial phases
| Period |
Market phase |
Financial implication |
| Initial launch and adoption |
Recombinant FSH gains acceptance against urinary-derived products |
Volume growth and premium pricing |
| Mature branded period |
Follistim and Gonal-f become established clinic standards |
Stable demand with competitive pricing |
| Current period |
Product differentiation shifts toward pen design, supply reliability and contracting |
Margin protection depends on execution |
| Follow-on competition period |
Potential biosimilars or lower-priced recombinant FSH products enter |
Price and share pressure |
Follistim’s value is therefore tied to franchise durability, not exclusivity-driven price expansion. The product can remain commercially relevant after core patents expire if Organon maintains supply, physician familiarity, device usability and payer access.
When does follitropin beta lose exclusivity?
The principal U.S. active-ingredient and platform protection for follitropin beta is mature. Follistim was approved in the 1990s, and the statutory five-year new chemical entity exclusivity period has long expired. Any original composition or manufacturing patents would also be expected to be expired or close to expiration based on the product’s launch date.
The commercial protection that remains is more likely to come from:
- Formulation and stability know-how.
- Cartridge and pen-device design.
- Manufacturing controls and validated cell-line processes.
- Trademark recognition.
- Distribution contracts.
- Regulatory complexity associated with follow-on biologic development.
A precise current expiration analysis requires review of the FDA regulatory record, historical U.S. patents, terminal disclaimers, patent-term adjustments and any patent litigation settlements. Public market data do not support treating an unverified patent date as a definitive exclusivity date.
What is the FDA regulatory status of Follistim?
Follistim is an FDA-approved recombinant FSH product. The Follistim AQ label covers ovarian stimulation and related fertility uses, subject to patient-selection and monitoring requirements. [1]
The product’s regulatory profile has three commercial effects:
- It is an established reference product with extensive clinical use.
- Its biologic manufacturing process creates a higher entry burden than a conventional generic injectable.
- A competing product may need a full biologics application or an abbreviated 351(k) biosimilar pathway, depending on its development strategy.
Because follitropin beta is a biologic, a conventional ANDA pathway is generally not the expected route for a highly similar recombinant competitor. FDA’s biosimilar framework requires analytical, nonclinical and clinical evidence sufficient to establish biosimilarity, with interchangeability requiring a higher evidentiary standard. [4]
What is the Orange Book and Purple Book status of follitropin beta?
The Orange Book primarily covers approved drug products submitted under an NDA. Biologic reference-product and biosimilar information is principally tracked through the FDA Purple Book. [5]
For Follistim, the relevant regulatory questions are:
- Whether the marketed presentation is listed under an NDA or biologics application structure.
- Which patents, if any, are listed in the Orange Book for the specific presentation.
- Whether a follow-on product has been approved under section 351(k).
- Whether FDA has designated any product as biosimilar or interchangeable to follitropin beta.
Follitropin beta does not have an established U.S. biosimilar competitive class comparable to major biologics such as adalimumab or trastuzumab. The absence of an approved biosimilar does not create new reference-product exclusivity. It indicates that development, market size, pricing and regulatory return have not yet produced a meaningful approved competitor.
Which companies are challenging the follitropin beta franchise?
The main competitive threat is not currently a named U.S. Paragraph IV generic challenger. It is substitution among fertility products.
Branded recombinant competition
Gonal-f, containing follitropin alfa, is the most direct branded substitute. Follitropin alfa and beta are highly similar recombinant FSH products but are not the same molecule designation for regulatory or commercial purposes. Clinics can select between them based on dosing, pen design, contracting, availability and physician preference.
Rekovelle competes through individualized dosing based on anti-Müllerian hormone and body weight. Its differentiation is dosing strategy rather than direct replication of Follistim’s formulation.
Biosimilar competition
A future follitropin beta biosimilar could target:
- The active ingredient.
- The same or similar route of administration.
- Comparable ovarian-stimulation indications.
- Lower acquisition cost for clinics and payers.
The practical challenge is that fertility drugs are used in protocols where treatment centers may prioritize predictable response, reliable supply and device familiarity over the lowest unit price. A biosimilar would still need strong analytical comparability and commercial access.
Paragraph IV risk
No widely reported, active U.S. Paragraph IV campaign against Follistim is established in the public record. Paragraph IV litigation is more characteristic of small-molecule ANDA products. A follow-on follitropin beta developer would more likely pursue a biologics pathway and address any applicable patent rights through the patent dance and related federal litigation framework.
What formulations and devices are protected?
Follistim’s commercial differentiation is closely tied to the Follistim Pen and cartridge system. The delivery format is relevant because fertility treatment requires repeated dosing during ovarian stimulation.
The principal protection layers are likely to include:
- Cartridge compatibility.
- Dose-delivery accuracy.
- Pen mechanics.
- Drug stability during storage and use.
- Container-closure integrity.
- Manufacturing consistency.
- Device usability and patient training materials.
Device protection can delay practical substitution even after active-ingredient patents expire. It does not necessarily prevent a competitor from selling the same active ingredient in a vial, prefilled syringe or separate pen. Instead, it protects a commercial delivery ecosystem and can support physician and patient retention.
How strong is the patent estate for follitropin beta?
The patent estate is commercially moderate but weak on classic molecule exclusivity.
| Protection category |
Current assessment |
| Active ingredient |
Mature and unlikely to provide meaningful new exclusivity |
| Original recombinant production |
Historically important; likely expired or commercially aged |
| Formulation |
Potentially relevant, but scope depends on surviving claims |
| Pen and cartridge |
More likely to support product differentiation |
| Manufacturing know-how |
Potentially important and difficult to design around |
| Trademark |
Provides brand protection but not generic exclusion |
| Regulatory exclusivity |
Expired for the original launch-era product |
Manufacturing know-how may be more important than patent count. Recombinant FSH products require control of glycosylation, potency, impurities, aggregation and batch consistency. A technically compliant competitor still must establish reliable commercial-scale manufacturing and clinical performance.
What generic entry risks exist for Follistim?
The near-term risk is gradual price erosion rather than an abrupt generic cliff.
Low-risk scenario
Follistim retains share because no biosimilar launches, Organon maintains supply and clinics continue to value the pen system. Revenue remains broadly stable but may decline through ordinary pricing pressure.
Moderate-risk scenario
A competing recombinant FSH gains payer preference or clinic-contract share. Follistim volume declines, while Organon preserves part of the margin through contracting and patient support.
High-risk scenario
A biosimilar or technically substitutable follow-on product launches with materially lower pricing, receives broad payer coverage and achieves clinic adoption. Follistim could face both unit loss and price compression.
Automatic substitution would depend on FDA interchangeability status and state pharmacy-substitution rules. A biosimilar without interchangeability may still compete effectively through physician prescribing and institutional purchasing.
What licensing deals affect follitropin beta?
The major strategic transaction affecting Follistim was the separation of Merck’s established brands and women’s health operations into Organon in 2021. The transaction changed corporate ownership and commercial accountability but did not create new active-ingredient exclusivity. [2]
No publicly disclosed licensing transaction is required to explain the current U.S. market position of Follistim. The product’s economics are primarily determined by Organon’s ownership, manufacturing arrangements, commercial contracts and fertility-portfolio strategy.
How does follitropin beta compare with follitropin alfa?
| Factor |
Follitropin beta |
Follitropin alfa |
| Example brand |
Follistim AQ |
Gonal-f |
| Product class |
Recombinant FSH |
Recombinant FSH |
| Main competition |
Gonal-f and other gonadotropins |
Follistim and other gonadotropins |
| U.S. market maturity |
Mature |
Mature |
| Differentiation |
Pen, cartridge, brand history, contracting |
Pen, cartridge, brand history, contracting |
| Exclusivity outlook |
Mature biologic franchise |
Mature biologic franchise |
| Main entry risk |
Follow-on biologic or substitution |
Follow-on biologic or substitution |
| Revenue disclosure |
Not reported standalone by Organon |
Not generally reported standalone by commercial owner |
The two products compete more on execution and access than on large clinical distinctions. Treatment centers often manage both products within broader stimulation protocols.
What is the outlook for follitropin beta?
Follitropin beta should remain a commercially relevant fertility biologic, but its growth profile is likely to be modest. The product has durable demand, strong clinical familiarity and an established delivery system. It lacks the patent-based pricing power associated with newly launched biologics.
The key indicators for investors and business-development teams are:
- Organon’s fertility-product volume and price commentary.
- Follistim supply continuity.
- Clinic and payer contracting changes.
- FDA Purple Book activity involving recombinant FSH products.
- Patent filings covering cartridges, pens and formulations.
- Entry of biosimilar or follow-on FSH products.
- ART cycle growth and reimbursement expansion.
- Relative pricing against Gonal-f, Rekovelle and menotropins.
Key Takeaways
- Follitropin beta is a mature recombinant FSH biologic marketed primarily as Follistim AQ.
- Organon owns the principal U.S. commercial franchise following the 2021 Merck separation.
- Standalone Follistim revenue is not publicly disclosed.
- Core molecule and launch-era exclusivity are mature; remaining value is concentrated in the brand, delivery device, manufacturing know-how and commercial relationships.
- Gonal-f is the closest branded competitor.
- The principal future entry risk is a biosimilar or other follow-on recombinant FSH product, not a traditional small-molecule Paragraph IV generic.
- Financial performance is likely to reflect stable fertility demand offset by contracting, price pressure and substitution risk.
- No established U.S. biosimilar or active Paragraph IV campaign against Follistim is widely reported.
FAQs
Is follitropin beta the same as follitropin alfa?
No. Both are recombinant FSH products with similar therapeutic roles, but follitropin beta and follitropin alfa are distinct product designations and are marketed under separate brands.
Is Follistim a biosimilar?
No. Follistim is an originator recombinant FSH product. A biosimilar would need to demonstrate high similarity to the applicable FDA reference product under the section 351(k) pathway.
Can pharmacies automatically substitute a competing FSH product for Follistim?
Automatic substitution depends on FDA interchangeability status and applicable state law. Physician prescribing, payer policy and fertility-clinic purchasing also control actual product selection.
Does Follistim have a meaningful patent moat?
Its active-ingredient patent moat is mature. Its remaining commercial defenses are more likely to involve the pen, cartridge, formulation, manufacturing process, trademark and customer relationships.
What would most improve Follistim’s financial outlook?
The strongest commercial drivers would be growth in ART treatment volume, improved reimbursement, stable clinic contracts, reliable supply and the absence of a lower-priced follow-on biologic.
References
- U.S. Food and Drug Administration. (2023). Follistim AQ (follitropin beta injection) prescribing information.
- Organon & Co. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Centers for Disease Control and Prevention. (2024). 2022 assisted reproductive technology fertility clinic and national summary report.
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
